Valneva Announces FDA Approval of IXIARO® Shelf Life Extension to 36 Months; New US Military RFP Issued
Saint Herblain (France), March 8, 2020 Valneva SE (Valneva or the Company), today announced that the Food and Drug Administration (FDA) has approved the extension of the shelf life of its Japanese encephalitis vaccine IXIARO from 24 months to 36 months.
- Saint Herblain (France), March 8, 2020 Valneva SE (Valneva or the Company), today announced that the Food and Drug Administration (FDA) has approved the extension of the shelf life of its Japanese encephalitis vaccine IXIARO from 24 months to 36 months.
- Separately, the US Department of Defense (DoD) has issued a Request for Proposal (RFP) for Japanese Encephalitis Vaccine.
- Valneva will respond to this RFP expeditiously and, if successful, expects to enter into a new supply contract during the first half of 2020.
- Franck Grimaud, Valnevas Chief Business Officer, commented, We are pleased to receive this valuable shelf life extension for IXIARO in the US.